JP2007516169A5 - - Google Patents

Download PDF

Info

Publication number
JP2007516169A5
JP2007516169A5 JP2006516555A JP2006516555A JP2007516169A5 JP 2007516169 A5 JP2007516169 A5 JP 2007516169A5 JP 2006516555 A JP2006516555 A JP 2006516555A JP 2006516555 A JP2006516555 A JP 2006516555A JP 2007516169 A5 JP2007516169 A5 JP 2007516169A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
heteroaryl
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006516555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007516169A (ja
JP4680897B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/001989 external-priority patent/WO2005000303A1/en
Publication of JP2007516169A publication Critical patent/JP2007516169A/ja
Publication of JP2007516169A5 publication Critical patent/JP2007516169A5/ja
Application granted granted Critical
Publication of JP4680897B2 publication Critical patent/JP4680897B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006516555A 2003-06-27 2004-06-14 Gsk−3阻害薬としてのピラゾロ[3,4−b]ピリジン−6−オン類 Expired - Fee Related JP4680897B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48348903P 2003-06-27 2003-06-27
PCT/IB2004/001989 WO2005000303A1 (en) 2003-06-27 2004-06-14 Pyrazolo`3,4-b!pyridin-6-ones as gsk-3 inhibitors

Publications (3)

Publication Number Publication Date
JP2007516169A JP2007516169A (ja) 2007-06-21
JP2007516169A5 true JP2007516169A5 (enExample) 2007-08-02
JP4680897B2 JP4680897B2 (ja) 2011-05-11

Family

ID=33552061

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006516555A Expired - Fee Related JP4680897B2 (ja) 2003-06-27 2004-06-14 Gsk−3阻害薬としてのピラゾロ[3,4−b]ピリジン−6−オン類

Country Status (11)

Country Link
US (1) US7300943B2 (enExample)
EP (1) EP1641454B1 (enExample)
JP (1) JP4680897B2 (enExample)
AT (1) ATE409480T1 (enExample)
BR (1) BRPI0411891A (enExample)
CA (1) CA2529083A1 (enExample)
DE (1) DE602004016850D1 (enExample)
DK (1) DK1641454T3 (enExample)
ES (1) ES2313014T3 (enExample)
MX (1) MXPA05014201A (enExample)
WO (1) WO2005000303A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541367B2 (en) 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス,インコーポレイティド 神経発生のgaba受容体媒介調節
WO2007076055A2 (en) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
EP2001462A4 (en) * 2006-03-08 2010-02-24 Univ Maryland INHIBITION OF MICROTUBULUS PROTRUSION IN CANCER CELLS
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2008074788A (ja) * 2006-09-22 2008-04-03 Rohto Pharmaceut Co Ltd エラスチン産生促進剤
US8022085B2 (en) * 2007-05-07 2011-09-20 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof
WO2008137176A1 (en) * 2007-05-07 2008-11-13 Amgen Inc. Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use
US20100210644A1 (en) * 2007-06-25 2010-08-19 Boehringer Ingelheim International Gmbh Chemical compounds
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
JP5647519B2 (ja) 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ[d][1,3]ジオキソールおよびその誘導体の合成
GB0719299D0 (en) 2007-10-03 2007-11-14 Optinose As Nasal delivery devices
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
CN117836296A (zh) * 2021-08-03 2024-04-05 百济神州有限公司 吡唑并吡啶酮化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE138773C (enExample)
US4020072A (en) * 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
DD138773A1 (de) * 1978-09-15 1979-11-21 Helmut Dorn Verfahren zur herstellung von 6,7-dihydro-6-oxo-pyr&zolo eckige klammer auf 3,4-b eckige klammer zu-pyridinen
WO2002024694A1 (en) * 2000-09-22 2002-03-28 Smithkline Beecham, P.L.C. Pyrazolopyridines and pyrazolopyridazines as antidiabetics
EP1347972A1 (en) * 2000-12-19 2003-10-01 Smithkline Beecham Plc Pyrazolo 3,4-c]pyridines as gsk-3 inhibitors
GB0128287D0 (en) * 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds

Similar Documents

Publication Publication Date Title
JP2007516169A5 (enExample)
JP2006521343A5 (enExample)
JP7050666B2 (ja) デングウイルス複製阻害剤としての一または二置換インドール誘導体
CA2541832A1 (en) Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors
JP2007508290A5 (enExample)
JP7045984B2 (ja) デングウイルス複製阻害剤としての一または二置換インドール誘導体
JP2008524328A5 (enExample)
CA2680246A1 (en) Piperazinyl-propyl-pyrazole derivatives as dopamine d4 receptor antagonists, and pharmaceutical compositions containing the same
CA2525245A1 (en) Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors
TW201300384A (zh) 新穎的雙環吡啶酮類
KR101886945B1 (ko) 감마-세크레타제 조절제로서의 크로멘 및 1,1a,2,7b-테트라히드로시클로프로파[c]크로멘 피리도피라진디온
KR20140138293A (ko) 3,5-다이아미노피라졸 키나아제 억제제
JP2010533715A5 (enExample)
JP2005516969A (ja) メタボトロピックグルタミン酸受容体−5のヘテロアリール置換ピロールモジュレーター
JP2006507355A5 (enExample)
WO2005035501A1 (ja) 新規オレフィン誘導体
SI3107900T1 (en) DERIVATIVES OF 5-BENZYLISOQUINOLINE FOR CARRYING OUT OF CARDIOVASCULAR DISEASES
JP2007502258A (ja) バニロイド受容体モジュレーターとして用いるためのピペリジン/シクロヘキサンカルボキサミド誘導体
CN108699021A (zh) 新的杂环抗雌激素
AU2007258506A1 (en) 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
CN101243073A (zh) 5-ht1a受体的哌嗪-哌啶拮抗剂与激动剂
JP2005511566A (ja) 置換インドール、その製造方法、および痛みを抑えるためのその使用
ZA200602072B (en) Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists
CN102140081A (zh) 制备抑制香草素亚型1(vr1)受体的吲唑基脲的方法
US20080119481A1 (en) Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline